HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Ligand activation of peroxisome proliferator-activated receptor-beta/delta and inhibition of cyclooxygenase-2 enhances inhibition of skin tumorigenesis.

Abstract
Ligand activation of peroxisome proliferator-activated receptor (PPAR)-beta/delta and inhibition of cyclooxygenase-2 (COX-2) activity by nonsteroidal anti-inflammatory drugs can attenuate skin tumorigenesis. There is also evidence that attenuation of skin tumorigenesis by inhibition of COX-2 activity occurs through PPARbeta/delta-independent mechanisms. The present study examined the hypothesis that combining ligand activation of PPARbeta/delta with inhibition of COX-2 activity will cooperatively inhibit chemically induced skin tumor progression using both in vivo and ex vivo models. A two-stage chemical carcinogenesis bioassay was performed in wild-type and Pparbeta/delta-null mice. After 22 weeks, cohorts of both mouse lines were divided into four experimental groups: (1) control, (2) topical application of the PPARbeta/delta ligand GW0742, (3) dietary administration of the COX-2 inhibitor nimesulide, or (4) both GW0742 and nimesulide. Ligand activation of PPARbeta/delta did not influence skin tumor progression, while a modest decrease in skin tumor multiplicity was observed with dietary nimesulide. Interestingly, the combined treatment of GW0742 and nimesulide increased the efficacy of the decrease in papilloma multiplicity for 6 weeks in wild-type mice, but this effect was not found at later time points and was not found in similarly treated Pparbeta/delta-null mice. Neoplastic keratinocyte lines cultured with GW0742 and nimesulide also exhibited enhanced inhibition of cell proliferation coincident with increased expression of Keratin messenger RNAs. Results from these studies support the hypothesis that combining ligand activation of PPARbeta/delta with inhibition of COX-2 activity can inhibit chemically induced skin tumor progression by modulating differentiation.
AuthorsMoses T Bility, Bokai Zhu, Boo H Kang, Frank J Gonzalez, Jeffrey M Peters
JournalToxicological sciences : an official journal of the Society of Toxicology (Toxicol Sci) Vol. 113 Issue 1 Pg. 27-36 (Jan 2010) ISSN: 1096-0929 [Electronic] United States
PMID19748995 (Publication Type: Journal Article, Research Support, N.I.H., Extramural)
Chemical References
  • Anticarcinogenic Agents
  • Cyclooxygenase 2 Inhibitors
  • Ligands
  • PPAR delta
  • PPAR-beta
  • RNA, Messenger
  • Sulfonamides
  • Thiazoles
  • (4-(((2-(3-fluoro-4-(trifluoromethyl)phenyl)-4-methyl-1,3-thiazol-5-yl)methyl)sulfanyl)-2-methylphenoxy)acetic acid
  • 9,10-Dimethyl-1,2-benzanthracene
  • Keratins
  • Dinoprostone
  • nimesulide
Topics
  • 9,10-Dimethyl-1,2-benzanthracene
  • Animals
  • Anticarcinogenic Agents (pharmacology)
  • Carcinoma, Squamous Cell (enzymology, prevention & control)
  • Cell Differentiation (drug effects)
  • Cell Line, Tumor
  • Cell Proliferation (drug effects)
  • Cyclooxygenase 2 Inhibitors (pharmacology)
  • Dinoprostone (metabolism)
  • Disease Models, Animal
  • Female
  • Keratinocytes (drug effects, enzymology, pathology)
  • Keratins (genetics)
  • Keratoacanthoma (enzymology, prevention & control)
  • Ligands
  • Mice
  • Mice, Inbred C57BL
  • Mice, Knockout
  • PPAR delta (agonists, deficiency, genetics, metabolism)
  • PPAR-beta (agonists, deficiency, genetics, metabolism)
  • Papilloma (enzymology, prevention & control)
  • RNA, Messenger (metabolism)
  • Skin Neoplasms (chemically induced, enzymology, pathology, prevention & control)
  • Sulfonamides (pharmacology)
  • Thiazoles (pharmacology)
  • Time Factors

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: